Squarepoint
PGNX

Squarepoint’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Squarepoint’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,779
Closed -$68K – 2681
2020
Q1 		$68K Buy
+17,779
New +$76.6K ﹤0.01% 1698
2019
Q3 		– Sell
-115,461
Closed -$712K – 2830
2019
Q2 		$712K Sell
115,461
-32,015
-22% -$154K 0.01% 1456
2019
Q1 		$684K Sell
147,476
-39,143
-21% -$177K 0.01% 1314
2018
Q4 		$784K Buy
+186,619
New +$950K 0.01% 1031
2018
Q2 		– Sell
-118,973
Closed -$888K – 2197
2018
Q1 		$888K Buy
118,973
+49,661
+72% +$330K 0.01% 853
2017
Q4 		$412K Buy
69,312
+19,768
+40% +$120K 0.01% 1317
2017
Q3 		$365K Sell
49,544
-45,588
-48% -$290K 0.01% 1094
2017
Q2 		$646K Buy
95,132
+40,833
+75% +$301K 0.01% 863
2017
Q1 		$513K Buy
54,299
+13,740
+34% +$137K 0.01% 847
2016
Q4 		$350K Buy
40,559
+29,460
+265% +$218K 0.01% 1057
2016
Q3 		$70K Buy
+11,099
New +$67.1K ﹤0.01% 968
2016
Q1 		– Sell
-41,300
Closed -$253K – 1560
2015
Q4 		$253K Buy
+41,300
New +$271K 0.03% 878
2015
Q2 		– Sell
-26,972
Closed -$161K – 662
2015
Q1 		$161K Buy
+26,972
New +$170K 0.06% 386

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Squarepoint's PGNX Position: Q2 2020 in Review

Squarepoint sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 17,779 shares — an estimated $68K sold.

Squarepoint first reported a position in PGNX in Q1 2015 and held it in 13 quarters. The position peaked at $888K in Q1 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Squarepoint reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Squarepoint sold 17,779 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $68K.
  • Squarepoint first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 13 quarters.
  • Squarepoint's Progenics Pharmaceuticals Inc position peaked at $888K in Q1 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Squarepoint's 13F filing for Q2 2020, filed 14 Aug 2020.